More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

How are biologics faring in terms of new drug approvals? DCAT Value Chain Insights examines biologic-based APIs approved as new molecular entities by the FDA’s Center for Drug Evaluation and Research thus far in 2020 and recent trends. Biologics...

What are the latest developments in upstream and downstream bioprocessing? DCAT Value Chain Insights provides a roundup of CDMO/CMO expansions in biomanufacturing and manufacturing for cell and gene therapies. CDMO/CMO expansions CDMO/CMOs have...

An upcoming DCAT webinar, featuring Graham Lewis, Vice President, Global Pharma Strategy, IQVIA, evaluates the market impact on the COVID-19 pandemic on companies’ pipelines, product launches, and performance and how industry fundamentals and...

What are the key developments from the large pharmaceutical companies’ pipelines expected for later this year? Which new drugs or additional indications for existing drugs have blockbuster potential? DCAT Value Chain Insights takes an inside...

The UK and the European Union (EU) are resuming negotiations this week (September 29 to October 2, 2020) for a deal that would define the UK’s future relationship with the EU post Brexit. As the clock winds down to reach a deal or not, the pharma...

The rise in the number of orphan-drug approvals and an increase in the development of more targeted therapies with smaller patient populations results in lower-volume drugs. What is the impact on production economics, and how can pharma companies...

Buoyed by $2 billion in funding by the private equity firm, Blackstone, a $1-billion partnering deal with Regeneron Pharmaceuticals, and potential gains from a possible blockbuster anti-cholesterol drug it has licensed to Novartis, Alnylam...

The FDA has issued guidance to advise drug manufacturers how to resume normal manufacturing operations that were impacted by the COVID-19 pandemic, which has caused unusual challenges: employee illness and absenteeism, travel restrictions, site...

Injectable drugs are assuming a larger role in recent drug approvals and drug development owing to the increase in biologic-based drug development and complexity of APIs, which make injectable delivery a preferred option due to molecule size,...